Drug Therapy Options for Patients with Irritable Bowel Syndrome

New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.

Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.

Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.

AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.

A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers

Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.